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Herestraat, 49, BE-3000 Leuven, BelgiumThis volume on Congenital Disorders of Glycosylation (CDG)
appears 10 years after the magniﬁcent BBA volume on the Molecular
Basis of Glycoconjugate Diseases edited by Harry Schachter [1]. We
are very happy and proud that this charming “pope” of glycobiology
has in turn agreed to contribute to the present volume. In these 10
years, CDG (formerly called Carbohydrate-deﬁcient Glycoprotein
Disorders) have come of age. In 1999, only 6 CDG were known: in a
mutase (CDG-Ia), an isomerase (CDG-Ib), a glucosyltransferase (CDG-
Ic), a mannosyltransferase (CDG-Id), an N-acetylglucosaminyltrans-
ferase (CDG-IIa), and a galactosyltransferase (B4GALT7 defect). This
number has increased to more than 40 by now including also defects
in glycosidases, chaperons, oligosaccharyltransferase, transporters, a
kinase and a ﬂippase (see synoptic table in [2]). Besides the known
defects in protein N-glycosylation and protein O-glycosylation, new
subfamilies have emerged in particular the combined protein N- and
O-glycosylation defects, dolichol metabolism defects, glycosylpho-
sphatidylinositol anchor defects and glycolipid synthesis defects.
Moreover, genetic diseases due to hyperglycosylation have been
recognized [3].
Besides a large repertoire of neurological and other symptoms, an
increasing number of known speciﬁc syndromes have been identiﬁed
as glycosylation disorders. Examples of these are the hereditary
multiple exostoses, the congenital muscular dystrophies, Peters plus
syndrome, leukocyte adhesion deﬁciency type II, autosomal recessive
hereditary inclusion body myopathy, the allelic disorders hyperpho-
sphatemic familial tumoral calcinosis and cortical hyperostosis with
hyperphosphatemia, spondylocostal dysostosis type 3 and cutis laxa
type II.
Over those 10 years, we have been witnessing a growing and
fruitful international collaboration on research in CDG. At the same
time, the awareness has been increasing, to the extent that more
patients are being identiﬁed worldwide, year after year. These do not
only include the typical and known cases but also lead to a growing
list of unsolved cases. The latter then become the subject of further
research promoting our insights in glycosylation and its diseases. The
medical and rare disease community has seldom seen such close
interactions between clinical and basic research. Two European
projects, Euroglycan and its successor, Euroglycanet, have signiﬁcant-
ly contributed to the success. And now that the funding by the
European Commission is drawing to its end, a larger international
collaboration is likely to emerge because, also in the USA, a diagnostic
and research network on CDG has been formed.
Finally, we would like to use the publication of this compilation
of papers on CDG to honour a colleague and friend who has spent
much of his research career on the study of glycosylation. It is a
great pleasure to dedicate this special issue to Eric Berger on
occasion of his retirement as professor of physiology at the
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